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UTIs, E. COLI ABUs, AND UPEC
Mucosal surfaces in the intestinal, respiratory, and urogen-
ital tracts are populated by a highly diverse bacterial flora.
Most host-dwelling bacteria are commensals and maintain a
symbiotic relationship with the host; however, a minority are
pathogens that attack the mucosa, causing tissue damage and
disease symptoms. Bacterial pathogens differ from commensals
by the expression of specific virulence factors, such as those
that mediate tissue assault. Commensals, in contrast, have gen-
erally been regarded as bacteria lacking such virulence factors
or other specific mechanisms for interaction with host tissues.
Asymptomatic carriage of bacteria may also result after a pri-
mary symptomatic infection. However, this type of carrier state
differs from commensalism in that variants of pathogenic
strains persist without evoking a host response. This review is
focused on the molecular basis for attenuation of virulence and
adaptation to commensalism, using the prototypic asymptom-
atic bacteriuria strain Escherichia coli 83972 as a model.
Most E. coli strains coexist peacefully with their human host,
while others cause disease. E. coli is a versatile pathogen caus-
ing a spectrum of diseases, including urinary tract infections
(UTIs), diarrhea, sepsis, and meningitis (28). UTIs are among
the most common infectious diseases of humans and are a
major cause of morbidity. It is estimated that 40 to 50% of
healthy adult women have experienced at least one UTI epi-
sode (15). Acute pyelonephritis and asymptomatic bacteriuria
(ABU) represent the two extremes of UTI. Escherichia coli is
responsible for 80% of UTIs. Acute pyelonephritis is a se-
vere acute systemic infection caused by uropathogenic E. coli
(UPEC) clones with virulence genes clustered on “pathogenic-
ity islands” (13, 16, 25, 46, 67, 72). ABU, on the other hand, is
an asymptomatic carrier state that resembles commensalism.
Paradoxically, a large proportion of UTIs are caused by ABU
E. coli. Individuals infected with ABU group E. coli may carry
high urine titers of a single E. coli strain for months or years
without provoking a host response. According to conventional
notions, pathogens can develop from commensals by the ac-
quisition of virulence-associated genes located on, for example,
pathogenicity islands or plasmids. The flip side of this evolu-
tionary force is the equally important adaptation of the newly
minted pathogen to its new host niche, where genes are inac-
tivated by either point mutation, insertion, or deletion (39).
Here we illustrate such an example, where the commensal-to-
pathogen shift in E. coli is bidirectional.
STRAIN 83972 AS A PROPHYLACTIC AGENT
E. coli 83972 is a prototype ABU strain and is probably the
best-characterized ABU-type E. coli strain to date. It is a clin-
ical isolate capable of long-term bladder colonization. The
strain lacks defined O and K surface antigens and is nonmotile
(2). Also, electron microscopy of 83972 did not reveal the
presence of flagella or a capsule (30, 56). Strain 83972 was
originally isolated from a young Swedish girl with ABU who
had carried it for at least 3 years without symptoms (2, 37). It
is well adapted for growth in the urinary tract (UT), where it
establishes long-term bacteriuria (2, 23, 75).
A number of studies have compared the outcomes of treated
versus untreated cases of ABU (20, 36, 66). These studies
concluded that not only do patients with ABU not profit from
antibiotic treatment, but also, if left untreated, they actually
have a reduced risk of kidney infection. Treatment of ABU is
generally recommended only for pregnant women, in whom
complications might arise (44). These observations and the
nonvirulent attributes of strain 83972 inspired a number of
studies in which 83972 was used for prophylactic purposes in
patients with recurrent UTI. In these studies, the bladders of
patients were deliberately colonized with strain 83972 in order
to prevent the establishment of UPEC and other uropatho-
gens. Strain 83972 has been used successfully in several such
studies and has been shown to establish bacteriuria without
jeopardizing the health of the patient. In one study, women
with chronic symptomatic UTI were treated for eradication of
their infection and then deliberately colonized with E. coli
83972. Stable bacteriuria was established for more than 30 days
in 7 of the 12 individuals (2). In another study, a group of
patients with recurrent symptomatic UTI had their bladders
deliberately colonized with E. coli 83972. Successful long-term
colonization (5 months to 3 years) was achieved in 6/12 pa-
tients with neurogenic bladder disorder (75). Deliberate colo-
nization with E. coli 83972 has also been shown to reduce the
frequency of UTI in patients with a neurogenic bladder sec-
* Corresponding author. Mailing address: Microbial Adhesion
Group, Center for Biomedical Microbiology, BioCentrum-DTU,
Technical University of Denmark, DK-2800 Lyngby, Denmark. Phone:
4545 252506. Fax: 4545 932809. E-mail: pkl@biocentrum.dtu.dk.
 Published ahead of print on 14 May 2007.
3688
 o
n
 O
ctober 14, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
ondary to spinal cord injury (23, 68), and the strain can prevent
catheter colonization by bacterial and fungal uropathogens
(10, 70, 71). Taken together, these studies have convincingly
indicated the potential of 83972 as a probiotic. Although not
yet approved by the U.S. FDA or a similar European authority
as a routine therapy, it has a safe and well-established track
record as an alternative treatment for patients with recalcitrant
infections in cases where conventional therapy has shown lim-
ited success.
STRAIN 83972 DOES NOT TRIGGER HOST DEFENSE
MECHANISMS AND LACKS FUNCTIONAL FORMS
OF THE PRIMARY UTI-ASSOCIATED ADHESINS
ABU patients may carry high urine titers of a single E. coli
strain for months or years without provoking a host response.
In early studies of ABU strains, it was suggested that this was
due to a lack of virulence genes, as the majority of ABU-
associated E. coli strains are nonhemolytic and nonadherent
and lack hemagglutination ability (13, 27, 37). Molecular epi-
demiology revealed, however, that 60% of ABU strains carry
virulence genes, even though they fail to express the corre-
sponding phenotype (49, 50, 55).
The ability of UPEC to cause symptomatic UTIs is enhanced
by adhesins (31, 45). Adherence to the UT epithelium enables
the bacterium to resist the hydrodynamic forces of urine flow
and to establish infection. The three primary fimbrial adhesive
organelles associated with urovirulence are P, type 1, and F1C
fimbriae. These three UPEC class fimbriae are all 7-nm-wide
and approximately 1-m-long surface polymers. The bulk of a
UPEC class fimbria is made up of about 1,000 subunits of a
major building element, viz, the PapA, FimA, or FocA protein,
for P, type 1, and F1C fimbriae, respectively. Additionally, a
few copies of minor components, for example, FimH in the
case of type 1 fimbriae, are integral parts of the fimbriae and
are responsible for their adhesive properties (33). The ability
of uropathogens to synthesize P fimbriae shows a very strong
correlation with clinical disease, and these adherence factors
have been shown to enhance the establishment of bacteriuria
and to activate the innate immune response in animal models
and in the human UT (5, 21, 52, 53). Type 1 fimbriae enhance
colonization and host response induction in the murine UTI
model and promote biofilm formation and invasion (8, 32, 43).
Type 1 fimbriae confer binding to -D-mannosylated proteins,
such as uroplakins, which are abundant in the bladder (8, 73),
while P fimbriae recognize the -D-galactopyranosyl-(1-4)--
D-galactopyranoside receptor epitope in the globoseries of gly-
colipids (35). Both P and type 1 fimbriae recognize their re-
ceptor targets by virtue of organelle tip-located adhesins,
namely, PapG and FimH, respectively (12, 63). The host re-
sponse includes cytokine production, inflammation, and exfo-
liation of infected epithelial cells (22, 43, 58, 74). F1C fimbriae
are expressed by a large proportion of UTI E. coli strains;
depending on the study, 14 to 30% of UTI strains have been
reported to be able to express these fimbriae (47, 60). F1C
fimbriae specifically recognize galactosylceramide targets
present on epithelial cells in the kidneys, ureters, and bladder,
as well as globotriaosylceramide, present only in the kidneys (4,
29). Recently, it was shown that human renal epithelial cells
specifically produce the proinflammatory cytokine interleu-
kin-8 in response to F1C fimbria-mediated attachment (4).
The ability of E. coli 83972 to establish efficient long-term
colonization of the human bladder without evoking counter-
measures from the host defense system is not fully understood.
The strain has been reported to carry genes of the pap, fim, and
foc gene clusters, encoding P, type 1, and F1C fimbriae, re-
spectively (24). However, the 83972 strain does not express
detectable fimbrial phenotypes when recovered from the UT
or after in vitro subculture and has never been reported to
adhere to any relevant cell targets (54). In an attempt to re-
solve this discrepancy, we recently investigated the genetic and
molecular status of the three UPEC class fimbriae in strain
83972 (30, 56). From these studies, it transpired that the strain
is unable to express any of these adhesins in a functional form.
It is interesting that the type 1, F1C, and P fimbrial systems of
E. coli 83972 have been incapacitated in quite different ways
(Fig. 1). In all cases, mutational events have inactivated the
fimbrial systems, but the underlying genetic events are quite
different, as follows. The type 1 system has been inactivated by
a major deletion encompassing 4.25 kb of the fim gene cluster,
affecting all genes except those encoding the minor compo-
nents, viz, fimF, fimG, and fimH. The F1C system has been
inactivated by point mutations in the fimbrial transport system,
affecting the focD gene, encoding the usher protein (56).
Meanwhile, the foc genes are still transcribed, and the major
structural protein, FocA, is produced, although it is unable to
reach the cell surface. This suggests that the inactivation of
FocD might be a recent evolutionary event. Interestingly,
strain 83972 still has the capacity to produce P fimbriae; how-
ever, these are unable to bind to their cognate receptor since
point mutations in the papG gene have rendered the PapG
adhesin nonfunctional (30). This also suggests that inactivation
of P fimbria functionality might be a recent evolutionary event
since, as in the case of the F1C system, strain 83972 is unable
to produce functional organelles but still wastes resources by
churning out fimbrial proteins.
STRAIN 83972 WAS ONCE A PATHOGEN
ABU patients may carry a single strain for months or years,
creating a condition that resembles commensalism, but with a
strain that may have evolved from a pathogenic ancestor. Sev-
eral lines of evidence support the notion that the ancestor of
strain 83972 was a pyelonephritic UPEC strain. First, multilo-
cus sequence typing of 83972 shows that it belongs to the B2
clonal group (http://www.mlst.net/). E. coli strains belonging to
group B2 are associated with pyelonephritis and other extraint-
estinal invasive clinical syndromes, such as bacteremia, pros-
tatitis, and meningitis. Second, the strain contains gene clusters
encoding the three primary UPEC class fimbriae in various
stages of erosion. Arguably, the ancestor of strain 83972 was
once able to express functional F1C, type 1, and P fimbriae.
Third, despite the fact that the fim and pap gene clusters of the
strain contain mutations that destroy their function, they con-
tain sequence information suggestive of a pathogenic past.
Thus, the fimH allele of 83972 encodes minor amino acid
variations (compared with the K-12 version) that are consistent
with those of previously characterized pyelonephritis isolates
(62–64). Finally, the strain has a copy of the F14 papA variant
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that has been associated with other virulence factors, including
hemolysin and cytotoxic necrotizing factor 1, from E. coli
strains in the B2 phylogenetic group (26).
STRAIN 83972 STAYS IN THE HUMAN BLADDER BY
VIRTUE OF A LACK OF HOST DEFENSE ACTIVATION,
FAST GROWTH, AND POSSIBLY BIOFILM FORMATION
Strain 83972 was carried by a young girl without any symp-
toms for 3 years. Later long-term carriage studies with 83972
have confirmed that the strain does not trigger a mucosal
response in patients and does not trigger host defense mech-
anisms. It seems that a major reason for the failure of 83972 to
trigger host defenses and to keep a low profile vis-a`-vis the
human host is its inability to express functional UPEC class
fimbriae (30, 56). Thus, it avoids the activation of aggressive
host countermeasures, such as the production of cytokines,
inflammation, and exfoliation of infected bladder epithelial
cells, and can continue to occupy its privileged environmental
niche.
Meanwhile, the lack of UPEC class fimbriae in strain 83972
raises the issue of how it is able to persist in a high-flow
environment like the human UT. Healthy adult humans nor-
mally produce 1 to 2 liters of urine per day, which must pass
through the bladder and corresponds to an average flow rate of
40 to 80 ml per hour. An adult human bladder has a holding
capacity of 200 to 400 ml, and micturition causes the release of
roughly the same volume of urine; the volume of residual urine
is about 1 milliliter (59). These would seem to be conditions
that are hardly compatible with colonization by a nonadherent
microbe. The contribution of bladder hydrodynamics to the
elimination of bacteria has been recognized for several de-
cades (6, 38), and it has even been suggested that without
adhesin-assisted attachment to the bladder surface, E. coli
would not be able to become established in the UT (3, 69).
Implicit in this suggestion is the notion that the growth rate of
E. coli in urine is too low to cope with the losses incurred by
micturition. Meanwhile, mathematical modeling indicates that
provided that the growth rate of a strain is high enough, it will
be able to become established in the bladder in an adhesion-
independent manner, and growth rates of E. coli isolated from
UTIs have been shown to be sufficient to overcome the losses
due to micturition (17). Indeed, strain 83972 grows extremely
well in human urine in vitro, with a doubling time of less than
45 min (57). Furthermore, we recently showed that the capac-
ity to grow fast in urine is not a unique property of 83972, since
several other ABU isolates also possess similar growth char-
acteristics (55). This suggests that fast growth in human urine
can account to a large degree for the ability of E. coli 83972 to
establish itself in the human bladder.
Bacterial biofilms can be established on virtually any solid
surface of organic or inorganic nature, spanning a wide spec-
trum of environments. More than 50% of all microbial infec-
tions have now been associated with the formation of biofilms
(9). Biofilm formation is generally considered to be important
for long-term bacterial establishment on surfaces subjected to
hydrodynamic flow, such as the human UT, since bacterial
biofilms are highly resistant to removal by liquid flow forces.
Indeed, previous studies have advocated the importance of
bacterial biofilm formation in UTIs, notably in chronic cystitis
and infections associated with catheters (42, 51). Recent stud-
ies of UTIs not associated with catheters support the notion
that the ability of UTI E. coli to form biofilms correlates with
persistence and recurrence (1, 34, 65). We recently studied
biofilm formation of strain 83972 on various surfaces in human
urine and found that it was an excellent biofilm former under
these conditions. In fact, our data suggested that biofilm for-
mation is associated with many ABU E. coli strains, but not
with UPEC strains, and may be an important strategy for
persistence in the high-flow environment of the UT (18, 19). In
FIG. 1. The E. coli ABU strain 83972 carries the fim, foc, and pap clusters, encoding type 1, F1C, and P fimbriae, respectively. However, all
three gene clusters have accrued mutations that destroy their function, rendering 83972 incapable of expressing functional fimbriae on the surface
of the cell (30, 56). The three fimbrial systems have been incapacitated in quite different ways (as indicated in gray). (A) The type 1 system has
been inactivated by a major deletion encompassing 4.25 kb of the fim gene cluster. (B) The F1C system has been inactivated by point mutations
in the fimbrial transport system, affecting the focD gene encoding the usher protein, making it impossible for the fimbrial components to reach the
cell surface. (C) The P system has been made nonfunctional by the introduction of point mutations in the papG gene: 83972 can produce P fimbriae,
but these are unable to bind to their cognate receptor.
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addition, global gene expression profiling of biofilm formation
of strain 83972 in human urine revealed similarities with the
expression profile in patients, indicating that biofilm formation
might play a role in efficient colonization of the human UT
(19). Taken together, a picture of how ABU strain 83972
manages to colonize the human UT is forming; the two pri-
mary strategies seem to be (i) fast growth and (ii) possible
biofilm formation.
HOW DOES 83972 KEEP UROPATHOGENS OUT?
The human bladder seems to be an attractive environmental
niche for a microorganism like strain 83972, with a steady
supply of nutrients, constant temperature, etc. Arguably, it
might be an advantage to keep competitors out. As previously
mentioned, strain 83972 has been used successfully for prophy-
lactic purposes in patients with recurrent UTIs, where it was
shown to prevent the establishment of uropathogens (10, 11,
23, 71). However, the underlying mechanisms for this phenom-
enon were not clear. The excellent growth characteristics of
83972 in urine prompted us to compete it with a range of
well-characterized UPEC strains (57). Indeed, it transpired
that when E. coli 83972 was pitted against the UPEC strains in
pairwise competition experiments, it outcompeted all of them
to a significant degree; competition against UPEC strain
CFT073, using a starting ratio of 1:1, resulted in a population
of cells that comprised 96% 83972 and 4% CFT073 after 17 h
of growth. Furthermore, in experiments using a starting ra-
tio of 1 (83972) to 20 (NU14), strain 83972 managed to totally
outcompete NU14 such that it comprised 93% of the final
population. Strain 83972 also grew faster than any of the
UPEC strains and displayed superior growth characteristics in
that it reached a higher maximum cell density and exhibited a
shorter lag phase in human urine. These results were con-
firmed in mouse experiments; the 83972 strain was almost
totally dominant in the urine of mice 24 h after they received
a mixed challenge consisting of 83972 and the UPEC isolate
NU14 (1:1). The prophylactic properties of 83972 against
UPEC strains therefore seem to be associated with its excellent
growth properties in human urine.
Meanwhile, in recent studies, we found that biofilm forma-
tion in human urine seems to be inversely related to uroviru-
lence (14, 18). Indeed, the biofilm-forming capacity of strain
83972 (and other selected ABU strains) was markedly superior
to that of the UPEC group. It is interesting that in our hands,
strain 83972, which has been shown to inhibit UT colonization
by uropathogens (70, 71), was able to outperform the UPEC
strain CFT073 completely with respect to biofilm formation in
a flow cell system (14, 18, 19). Furthermore, it was also dem-
onstrated that strain 83972 was able to exclude UPEC strains
during biofilm formation in human urine (14). The excellent
biofilm-forming faculty of strain 83972 might also contribute to
its ability to outcompete other microbes and to inhibit UT
infection and catheter colonization by uropathogens.
GLOBAL GENE EXPRESSION PROFILES OF 83972
IN URINE AND IN HUMAN HOSTS
The bacterial transcriptome is a dynamic entity that reflects
the organism’s immediate, ongoing response to its environ-
ment. DNA microarray-assisted functional genomics provides
the global expression profile of a genome, disclosing how the
bacterium adapts to an environmental niche. Global gene ex-
pression profiles of strain 83972 in human urine compared with
minimal medium revealed that the strain has adapted well to
growth in this iron-limiting environment. It does so by up-
regulation of its numerous iron uptake systems (57). Further-
more, the array data revealed high expression levels of genes
involved in transportation and degradation pathways of sugar
acids and carbohydrates (e.g., galacturonate, glucuronate,
galactonate, arabinose, sorbitol, galactose, maltose, xylose, and
mannose), indicating how E. coli 83972 is able to reach high
growth rates in human urine by efficiently utilizing the nutri-
ents available in this growth medium.
Global gene expression profiling of strain 83972 in the blad-
ders of three individuals revealed a number of interesting fac-
ets about the strain in vivo (54). Not only is it unable to express
functional forms of type 1, F1C, and P fimbriae because of
various genetic lesions, but also most of the fimbria-encoding
genes that are actually present turned out to be shut down in
human hosts. Furthermore, several other known virulence fac-
tors were also down-regulated in the bladder, such as genes
involved in hemolysin, lipopolysaccharide (LPS), and capsule
synthesis. This lends further support to the notion that 83972 is
a benign strain that does not harm the host and cannot trigger
host defense mechanisms.
It is interesting that the majority of the most highly ex-
pressed genes of E. coli 83972 in humans encode products that
are involved in protein synthesis, such as ribosome compo-
nents. The high expression of ribosomal genes in E. coli 83972
suggests a high growth rate in the human UT and supports our
hypothesis that the strain’s optimized growth properties in
human urine explain its ability to successfully colonize the
human UT in the absence of functional fimbriae. The data also
revealed that the strain has an impressive array of iron acqui-
sition systems and that all of these are active in the human
bladder. These characteristics might also contribute to its abil-
ity to grow fast in human urine and to outcompete UPEC
strains and other pathogens. The results further revealed an in
vivo lifestyle of microaerobic growth, with respiration of nitrate
coupled to degradation of sugar acids and amino acids. How-
ever, the use of sugar acids, amino acids, and carbohydrates
varied among the three patients (presumably due to urine
composition), and very few metabolic pathways were up-regu-
lated in all patients. One of the few commonly used nutrients
was D-serine: the two genes encoding D-serine deaminase and
permease, dsdA and dsdX, respectively, were up-regulated up
to 8.3-fold compared with their levels in minimal lab medium.
Interestingly, the expression profile for the strain in the human
UT showed partial overlap with the biofilm expression profile,
indicating a partial biofilm-like life of strain 83972 in the hu-
man UT (19).
COMPARISON OF TWO PROTOTYPIC STRAINS
The UTI E. coli strains 83972 and CFT073 are prototype
strains representing the two extremes of UTI strains and their
interaction modes vis-a`-vis the human host. One, 83972, is a
harmless commensal-like isolate causing asymptomatic infec-
tions, whereas the other, CFT073, a highly virulent pyelone-
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phritis isolate, is a bona fide virulent UPEC strain that causes
severe symptoms in the host. The prototypic strain CFT073
was originally isolated from the blood of a female patient with
a severe symptomatic UTI (40). CFT073 is able to express an
impressive armamentarium of virulence factors, including the
UPEC class fimbriae, hemolysin, the siderophore aerobactin,
flagella, the K2 capsule, and LPS. E. coli 83972, on the other
hand, is defunct in all three UTI-associated fimbrial clusters,
has never been reported to adhere to UT cells, is nonhemo-
lytic, and lacks flagella and defined O and K antigens. How-
ever, despite the fact that the two strains show very different
phenotypes and interactions with the host, both strains belong
to the same E. coli reference group, i.e., the B2 clonal group
associated with highly virulent strains. This suggests that the
ancestor of 83972 was quite similar to CFT073.
Strains 83972 and CFT073 have radically different strategies
for their interaction with the human host (Fig. 2). ABU strain
83972 avoids triggering host defense mechanisms, lives a com-
mensal-like existence in bladder urine, and does not ascend
further than the bladder. In contrast, strain CFT073 triggers
FIG. 2. Comparison of two prototypic UTI E. coli strains, the UPEC strain CFT073 and the ABU strain 83972. (A) Behavior of the prototype
strains in the human UT. (B) Properties of the two strains. UPEC CFT073 was isolated from the blood of a patient with acute pyelonephritis, and
its entire genome has been sequenced (72). The properties of E. coli 83972 were compiled from several studies (18, 30, 54, 56, 57).
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host defenses but is apparently able to fend for itself; it can
ascend to the kidneys and may even cause septicemia (40). It is
therefore highly interesting to compare the genetic repertoires
and expression profiles of the two strains. A simple assumption
would argue that gene products that are expressed under rel-
evant conditions, viz, in patients or animal models, by CFT073,
but not by 83972, are potential candidates for virulence factors.
While CFT073 showed up-regulation of type 1 fimbriae, he-
molysin, and microcin secretion, as well as genes involved in
capsular polysaccharide and LPS synthesis, during growth in
mice (61), E. coli 83972 failed to express virtually all known
virulence-associated gene products in humans (54). Further-
more, the global gene expression profile comparison of 83972
in humans and CFT073 in mice revealed some similarities;
both strains grow rapidly in the UT, as indicated by the up-
regulation of genes involved in the translational machinery,
and respond to iron limitation by the activation of genes re-
lated to iron acquisition. Meanwhile, in spite of its inability to
express virulence factors in urine, strain 83972 is able to out-
perform strain CFT073 with respect to both growth and biofilm
formation in urine (14, 18, 57).
CONCLUDING REMARKS
The long-term bacterial occupancy of a privileged host niche
such as the human bladder must involve adaptations to the
host environment. Strain 83972 had grown in the bladder of a
girl with ABU for at least 3 years (2). This represents a sub-
stantial number of generations, i.e., 30,000, assuming gener-
ation times comparable to those observed by us (57). During
this period, the strain must have adapted considerably to this
particular environmental niche. The strain lost the ability to
express functional UPEC class fimbriae, probably as an evolu-
tionary tradeoff with the host defense. This ensured that it did
not attract the attention of aggressive host defense mecha-
nisms, such as cytokine production, inflammation, and exfoli-
ation of infected bladder cells. However, in order to avoid
being flushed out of the system, it had to adapt to a particular
ecological niche, i.e., human urine as a growth medium, and to
optimize its growth rate to keep pace with the flow rate in the
bladder. Whether this happened during the three-plus years it
was carried by the particular girl or before then in other hosts
is not possible to conclude. It is interesting, however, that the
girl suffered from a voiding problem and was unable to empty
her bladder completely, thus leaving a considerable volume of
residual urine (2, 37). Arguably, this would provide strain
83972 with an ideal training environment for optimizing its
ability to grow in urine. In line with this notion, strain 83972
must have accrued genetic changes that have favored its fitness
for growth in urine. Human urine is a very complex growth
medium, and the composition of urine fluctuates daily. It is
known, however, that iron availability is a limiting factor. The
array data indicated that strain 83972 has adapted to growth in
this iron-limiting environment by significantly increasing the
expression of the majority of all known genes involved in iron
uptake and transport. In fact, it has adapted so well to its niche
that it can outcompete a wide range of aggressive uropatho-
gens.
Bacterial genomes are under constant change. New genes
are acquired by horizontal transfer, and old ones are lost by
mutations. It is thought that such changes in genetic repertoire
are the primary mechanisms of bacterial adaptation to new
environments. Evidence for constant expansion and retraction
of genomes has been observed in cases where complete ge-
nomes have been sequenced (7, 48). It is generally believed
that commensal E. coli can become pathogenic through the
acquisition of novel genetic information encoding virulence
factors and niche adaptation factors (28). Acquired genes
range from single units to large constellations of genes, such as
pathogenicity islands or plasmids. The loss of genetic material
has been observed to take place via mechanisms ranging from
large-scale deletions to single point mutations (7, 41). In con-
trast to organisms that have acquired genes for pathogenesis,
E. coli 83972 is an example of an organism that has adapted to
commensalism through gene loss and mutations. The relation-
ship between bacterium and host in a persistent infection is a
mutual tradeoff. In this case, the bacterium has lost its primary
colonization factors; however, having done so, it does not dam-
age the host and evades immune surveillance. In effect, the
strain has become domesticated to a degree where it does not
cause any symptoms, i.e., it has become benign.
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